Quote:
U.S. health officials on Monday authorized use of the first treatment for people with earlier-stage Covid-19 who aren’t hospitalized, filling a gap in treatment.
The U.S. Food and Drug Administration said Eli Lilly LLY 3.19% & Co.’s antibody drug should be used for patients ages 12 and up with mild to moderate Covid-19, based on a study showing it helped improve symptoms and kept many patients out of the hospital.
The FDA said the drug is authorized for patients at high risk of progressing to severe Covid-19, including people 65 and older, or who have certain chronic medical conditions. The drug shouldn’t be given to hospitalized patients, the FDA said, because it showed no clinical benefit in a study among such patients.
The drug’s authorization “provides health care professionals on the frontline of this pandemic with another potential tool in treating Covid-19 patients,” said Patrizia Cavazzoni, acting director of the FDA’s Center for Drug Evaluation and Research.
:flower::clap: